Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totaling 108,814 shares, a decrease of 33.9% from the September 30th total of 164,505 shares. Currently, 2.3% of the company’s stock are sold short. Based on an average daily trading volume, of 39,300 shares, the short-interest ratio is presently 2.8 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
View Our Latest Stock Report on SNOA
Sonoma Pharmaceuticals Price Performance
Shares of Sonoma Pharmaceuticals stock traded up $0.04 during trading on Tuesday, hitting $1.14. 19,682 shares of the company’s stock traded hands, compared to its average volume of 115,091. Sonoma Pharmaceuticals has a 1 year low of $0.85 and a 1 year high of $3.95. The business has a 50-day simple moving average of $1.24 and a 200-day simple moving average of $1.71. The stock has a market capitalization of $5.44 million, a P/E ratio of -0.93 and a beta of 1.30.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.32. The business had revenue of $6.41 million for the quarter, compared to analysts’ expectations of $4.99 million. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment.
The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions.
Further Reading
- Five stocks we like better than Sonoma Pharmaceuticals
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
